From Wikipedia, the free encyclopedia
  (Redirected from Thiabendazole)
Jump to: navigation, search
Thiabendazole ball-and-stick.png
Systematic (IUPAC) name
Clinical data
Trade names Mintezol
AHFS/Drugs.com International Drug Names
Legal status
  • AU: S4 (Prescription only)
  • (Prescription only)
Routes of
oral, topical
Pharmacokinetic data
Metabolism GI tract. Peak plasma 1-2 hours through oral administration
Biological half-life 8 hours
Excretion 90% I urine
CAS Number 148-79-8 YesY
ATC code D01AC06 P02CA02 QP52AC10
PubChem CID: 5430
DrugBank DB00730 N
ChemSpider 5237 N
KEGG D00372 YesY
NIAID ChemDB 007903
Chemical data
Formula C10H7N3S
Molecular mass 201.249 g/mol
Physical data
Density 1.103 g/cm3
Melting point 293 to 305 °C (559 to 581 °F)
 N (what is this?)  (verify)

Tiabendazole (INN, BAN), thiabendazole (AAN, USAN), TBZ (and the trade names Mintezol, Tresaderm, and Arbotect) is a fungicide and parasiticide.



It is used primarily to control mold, blight, and other fungal diseases in fruits (e.g. oranges) and vegetables; it is also used as a prophylactic treatment for Dutch elm disease.

Use in treatment of aspergillosis has been reported.[1]


As an antiparasitic, it is able to control roundworms (such as those causing strongyloidiasis),[2] hookworms, and other helminth species which attack wild animals, livestock and humans.[3]

Angiogenesis inhibitor[edit]

Genes responsible for the maintenance of cell walls in yeast have been shown to be responsible for angiogenesis in vertebrates. Tiabendazole serves to block angiogenesis in both frog embryos and human cells. It has also been shown to serve as a vascular disrupting agent to reduce newly established blood vessels. Tiabendazole has been shown to effectively do this in certain cancer cells [4]


TBZ works by inhibition of the mitochondrial, helminth-specific enzyme, fumarate reductase, with possible interaction with endogenous quinone.[5]


Medicinally, thiabendazole is also a chelating agent, which means it is used medicinally to bind metals in cases of metal poisoning, such as lead, mercury, or antimony poisoning.

In dogs and cats, thiabendazole is used to treat ear infections.

Thiabendazole is also used as a food additive,[6][7] a preservative with E number E233 (INS number 233). For example, it is applied to bananas to ensure freshness, and is a common ingredient in the waxes applied to the skins of citrus fruits. It is not approved as a food additive in the EU,[8] Australia and New Zealand.[9]


The substance appears to have a slight toxicity in higher doses, with effects such as liver and intestinal disorders at high exposure in test animals (just below LD50 level).[citation needed] Some reproductive disorders and decreasing weaning weight have been observed, also at high exposure. Effects on humans from use as a drug include nausea, vomiting, loss of appetite, diarrhea, dizziness, drowsiness, or headache; very rarely also ringing in the ears, vision changes, stomach pain, yellowing eyes and skin, dark urine, fever, fatigue, increased thirst and change in the amount of urine occur.[citation needed] Carcinogenic effects have been shown at higher doses.[10]


Thiabendazole synthesis:[11] L. H. Sarett, H. D. Brown, U.S. Patent 3,017,415 (1962 to Merck & Co.).

Intermediate arylamidine 2 is prepared by the AlCl3 catalyzed addition of aniline to the nitrile function of 4-cyanothiazole (1). Amidine (2) is then converted to its N-chloro analog 3 by means of NaOCl. On base treatment, this apparently undergoes a nitrene insertion reaction (4) to produce thiabendazole (5). Note the direction of the arrow is from the benzene to the nitrene since the nitrene is an electrophilic species.

Alternative route of synthesis: 4-thiazolecarboxamide with o-phenylenediamine in polyphosphoric acid.[12]

Synthesis of labeled thiabendazole:[13]


Cambendazole Prepn and activity studies:[14][15]

Cambendazole (best of 300 agents in an extensive study),[16] is made by nitration of tiabendazole, followed by catalytic hydrogenation to 2, and acylation with Isopropyl chloroformate.

See also[edit]


  1. ^ Upadhyay MP, West EP, Sharma AP (January 1980). "Keratitis due to Aspergillus flavus successfully treated with thiabendazole". Br J Ophthalmol 64 (1): 30–2. doi:10.1136/bjo.64.1.30. PMC 1039343. PMID 6766732. 
  2. ^ Igual-Adell R, Oltra-Alcaraz C, Soler-Company E, Sánchez-Sánchez P, Matogo-Oyana J, Rodríguez-Calabuig D (December 2004). "Efficacy and safety of ivermectin and thiabendazole in the treatment of strongyloidiasis". Expert Opin Pharmacother 5 (12): 2615–9. doi:10.1517/14656566.5.12.2615. PMID 15571478. 
  3. ^ Portugal R, Schaffel R, Almeida L, Spector N, Nucci M (June 2002). "Thiabendazole for the prophylaxis of strongyloidiasis in immunosuppressed patients with hematological diseases: a randomized double-blind placebo-controlled study". Haematologica 87 (6): 663–4. PMID 12031927. 
  4. ^ Cha, HJ; Byrom M; Mead PE; Ellington AD; Wallingford JB; et al. (August 2012). "Evolutionarily Repurposed Networks Reveal the Well-Known Antifungal Drug Thiabendazole to Be a Novel Vascular Disrupting Agent". PLoS Biology 10 (8). doi:10.1371/journal.pbio.1001379. Retrieved 2012-08-21. 
  5. ^ Gilman, A.G., T.W. Rall, A.S. Nies and P. Taylor (eds.). Goodman and Gilman's The Pharmacological Basis of Therapeutics. 8th ed. New York, NY. Pergamon Press, 1990., p. 970
  6. ^ Rosenblum C (March 1977). "Non-drug-related residues in tracer studies". Journal of Toxicology and Environmental Health 2 (4): 803–14. doi:10.1080/15287397709529480. PMID 853540. 
  7. ^ Sax, N.I. Dangerous Properties of Industrial Materials. Vol 1-3 7th ed. New York, NY: Van Nostrand Reinhold, 1989., p. 3251
  8. ^ UK Food Standards Agency: "Current EU approved additives and their E Numbers". Retrieved 2011-10-27. 
  9. ^ Australia New Zealand Food Standards Code"Standard 1.2.4 – Labelling of ingredients". Retrieved 2011-10-27. 
  10. ^ "Reregistration Eligibility Decision THIABENDAZOLE" (PDF). Environmental Protection Agency. Retrieved 8 January 2013. 
  11. ^ Grenda, V. J.; Jones, R. E.; Gal, G.; Sletzinger, M. (1965). "Novel Preparation of Benzimidazoles from N-Arylamidines. New Synthesis of Thiabendazole1". The Journal of Organic Chemistry 30: 259. doi:10.1021/jo01012a061. 
  12. ^ Brown, H. D.; Matzuk, A. R.; Ilves, I. R.; Peterson, L. H.; Harris, S. A.; Sarett, L. H.; Egerton, J. R.; Yakstis, J. J.; Campbell, W. C.; Cuckler, A. C. (1961). "Antiparasitic Drugs. Iv. 2-(4'-Thiazolyl)-Benzimidazole, A New Anthelmintic". Journal of the American Chemical Society 83 (7): 1764. doi:10.1021/ja01468a052. 
  13. ^ Tocco, D. J.; Buhs, R. P.; Brown, H. D.; Matzuk, A. R.; Mertel, H. E.; Harman, R. E.; Trenner, N. R. (1964). "The Metabolic Fate of Thiabendazole in Sheep1". Journal of Medicinal Chemistry 7 (4): 399. doi:10.1021/jm00334a002. 
  14. ^ Hoff, Fisher, ZA 6800351  (1969 to Merck & Co.), C.A. 72, 90461q (1970).
  15. ^ Hoff, D. R.; Fisher, M. H.; Bochis, R. J.; Lusi, A.; Waksmunski, F.; Egerton, J. R.; Yakstis, J. J.; Cuckler, A. C.; Campbell, W. C. (1970). "A new broad-spectrum anthelmintic: 2-(4-Thiazolyl)-5-isopropoxycarbonylamino-benzimidazole". Experientia 26 (5): 550. doi:10.1007/BF01898506. 
  16. ^ Chronicles of Drug Discovery, Book 1, pp 239-256.